Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Bundled Contracts To Defend Against Biosimilars May Face Payer Skepticism

Executive Summary

J&J plans to rely on its broad portfolio to contract favorably in a 'post-biosimilar world,' but cross-category bundling is generally discouraged by payers.

Advertisement

Related Content

J&J Maintains Strategy For Biosimilar Remicade As Inflectra Nears
Pfizer Sets Inflectra Launch Date; J&J Plans To Fight Back
JnJ Not Sweating Remicade Biosimilar Approval
Crohn's Pipeline: Janssen Seeks New Niche For Stelara As Biologics Use Rises

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register